NEW YORK, July 7 - RNA interference firms Alnylam and Ribopharma today said they have merged and that the combined entity has raised an additional round of  € 21.5 million ($24.6 million) in private equity financing.

 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Microsoft co-founder Paul Allen also contributed to brain research, NPR reports.

The New York Times reports on the shifting interpretations of what some genetic variants mean over time.

In Cell this week: investigation of metastatic tumor evolution, more than 16,000 genetic variants introduced into the budding yeast model organism, and more.

MIT's Technology Review reports on Genentech's pursuit of personalized cancer vaccines.